340B drug discounts only amounted to a small percentage of total drugmaker revenue, a hospital-funded study found.

340B Small Share of Drugmaker Revenue, Says Hospital-Backed Report

Despite the increase in the amount of 340B program drug discounts, those only amounted to 3.1% of global and 7% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.